The restoration
of balance

Pipeline

Resokine Pathway Discovery Pre-clinical Phase 1 Phase 2 Phase 3
ATYR1923 (iMod.Fc)
Interstitial Lung Disease
50%
ORCA
Various Cancers
30%
ATYR1940 (Resolaris™)
Rare Muscular Dystrophies
65%
tRNA Sythetase Pipeline Discovery Pre-clinical Phase 1 Phase 2 Phase 3
Multiple Discovery Programs

  • Internal Programs at aTyr
  • The Scripps Research Institute
  • Hong Kong University of Science and Technology

8%

Therapeutic Focus Phase
Resokine Pathway / Muscle
Resolaris for Adult FSHD Phase 1b/2
Resolaris for Early Onset FHSD Phase 1b/2
Resolaris for Adult LGMD2B Phase 1b/2
Resokine Pathway / Lung
iMod.Fc for Rare Lung Disease Pre-clinical
Resokine Pathway / Cancer
Project ORCA Pre-clinical
Physiocrine R&D
  Discovery

We intend to leverage our unique understanding of extracellular tRNA synthetase biology and our broad intellectual property portfolio, which we believe covers this entire class of potential protein therapeutics, to build a pipeline of product candidates that we expect to develop and commercialize independently for the treatment of various rare diseases.

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy